Patents by Inventor Benjamin Joseph Littler
Benjamin Joseph Littler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11773119Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: GrantFiled: August 20, 2020Date of Patent: October 3, 2023Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Corey Anderson, Sara Sabina Hadida Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Publication number: 20210238158Abstract: The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), useful for treating CFTR mediated diseases such as cystic fibrosis.Type: ApplicationFiled: August 26, 2020Publication date: August 5, 2021Applicant: Vertex Pharmaceuticals IncorporatedInventors: Gerald J. Tanoury, Cristian Harrison, Benjamin Joseph Littler, Peter Jamison Rose, Robert Michael Hughes, Young Chun Jung, David Andrew Siesel, Elaine Chungmin Lee, Daniel T. Belmont, William A. Nugent
-
Publication number: 20200377535Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: ApplicationFiled: August 20, 2020Publication date: December 3, 2020Inventors: Corey Anderson, Sara Sabina Hadida Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Patent number: 10822331Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention.Type: GrantFiled: December 27, 2018Date of Patent: November 3, 2020Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jean-Damien Charrier, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Robert Michael Hughes, David Andrew Siesel, Paul Angell, Armando Urbina, Yi Shi
-
Patent number: 10787472Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: GrantFiled: February 25, 2019Date of Patent: September 29, 2020Assignee: Vertex Pharmaceuticals IncorporatedInventors: Corey Anderson, Sara Sabina Hadida Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Patent number: 10435397Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention.Type: GrantFiled: December 27, 2018Date of Patent: October 8, 2019Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jean-Damien Charrier, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Robert Michael Hughes, David Andrew Siesel, Paul Angell, Armando Urbina, Yi Shi
-
Publication number: 20190276483Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: ApplicationFiled: February 25, 2019Publication date: September 12, 2019Inventors: Corey Anderson, Sara Sabina Hadida Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Publication number: 20190210991Abstract: The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)—N—(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), useful for treating CFTR mediated diseases such as cystic fibrosis.Type: ApplicationFiled: August 9, 2018Publication date: July 11, 2019Applicant: Vertex Pharmaceuticals IncorporatedInventors: Gerald J. Tanoury, Cristian Harrison, Benjamin Joseph Littler, Peter Jamison Rose, Robert Michael Hughes, Young Chun Jung, David Andrew Siesel, Elaine Chungmin Lee, Daniel T. Belmont, William A. Nugent
-
Publication number: 20190202818Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: wherein the variables are as defined herein.Type: ApplicationFiled: December 27, 2018Publication date: July 4, 2019Inventors: Jean-Damien Charrier, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Robert Michael Hughes, David Andrew Siesel, Paul Angell, Armando Urbina, Yi Shi
-
Patent number: 10253054Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: GrantFiled: October 24, 2017Date of Patent: April 9, 2019Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Corey Anderson, Sara Sabina Hadida-Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Patent number: 10208027Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: wherein the variables are as defined herein.Type: GrantFiled: December 20, 2017Date of Patent: February 19, 2019Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Robert Michael Hughes, David Andrew Siesel, Paul Angell, Armando Urbina, Yi Shi
-
Patent number: 10071979Abstract: The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), useful for treating CFTR mediated diseases such as cystic fibrosis.Type: GrantFiled: April 15, 2015Date of Patent: September 11, 2018Assignee: Vertex Pharmaceuticals IncorporatedInventors: Gerald J. Tanoury, Cristian Harrison, Benjamin Joseph Littler, Peter Jamison Rose, Robert Michael Hughes, Young Chun Jung, David Andrew Siesel, Elaine Chungmin Lee, Daniel T. Belmont, William A. Nugent
-
Publication number: 20180244662Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: wherein the variables are as defined herein.Type: ApplicationFiled: December 20, 2017Publication date: August 30, 2018Inventors: Jean-Damien Charrier, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Robert Michael Hughes, David Andrew Siesel, Paul Angell, Armando Urbina, Yi Shi
-
Publication number: 20180044361Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: ApplicationFiled: October 24, 2017Publication date: February 15, 2018Inventors: Corey Anderson, Sara Sabina Hadida-Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Patent number: 9862709Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: wherein the variables are as defined herein.Type: GrantFiled: April 3, 2015Date of Patent: January 9, 2018Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Robert Michael Hughes, David Andrew Siesel, Paul Angell, Armando Urbina, Yi Shi
-
Patent number: 9828397Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: GrantFiled: September 9, 2016Date of Patent: November 28, 2017Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Corey Anderson, Sara Sabina Hadida-Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Publication number: 20160376295Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: ApplicationFiled: September 9, 2016Publication date: December 29, 2016Inventors: Corey Anderson, Sara Sabina Hadida-Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Patent number: 9464102Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.Type: GrantFiled: September 18, 2015Date of Patent: October 11, 2016Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Corey Anderson, Sara Sabina Hadida-Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
-
Publication number: 20160166540Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.Type: ApplicationFiled: January 11, 2016Publication date: June 16, 2016Inventors: Adam Looker, Benjamin Joseph Littler, Anusuya Choudhury, Christian Harrison, Ravikanth Veluri, Michael P. Ryan, Licong Jiang, Eduard Luss-Lusis
-
Patent number: 9254291Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.Type: GrantFiled: November 8, 2012Date of Patent: February 9, 2016Assignee: Vertex Pharmaceuticals IncorporatedInventors: Adam Looker, Benjamin Joseph Littler, Anusuya Choudhury, Cristian Harrison, Ravikanth Veluri, Michael P. Ryan, Licong Jiang, Eduard Luss-Lusis